-
公开(公告)号:US20040009969A1
公开(公告)日:2004-01-15
申请号:US10301871
申请日:2002-11-22
申请人: Schering AG
发明人: Arwed Cleve , Christoph Huwe , Volker Schulze , Helmut Morack , Dieter Zopf , Jens Hoffmann , Andreas Reichel
IPC分类号: A61K031/538 , A61K031/496 , C07D413/02 , C07D49/02
CPC分类号: C07D207/452 , C07D233/86 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D417/14
摘要: This invention relates to new piperazine derivatives of general formula I, 1 in which V, W, n, R, Rnull, i, j, Y and Z have the meaning that is indicated in the description. The compounds according to the invention are distinguished by a diazacycloalkane substituent. They have at their disposal a special action with respect to the action that destabilizes the androgen receptor and can be used, for example, for treating prostate cancer.
摘要翻译: 本发明涉及通式I的新的哌嗪衍生物,其中V,W,n,R,R',i,j,Y和Z具有在说明书中指出的含义。 根据本发明的化合物由二氮杂环烷烃取代基区分。 他们有权采取行动,使雄激素受体不稳定,可用于治疗前列腺癌。